CA AB48

Requires prescribers to obtain signed informed written consent from nursing facility residents or their representatives before administering psychotherapeutic drugs, with material information provided in accessible language.

Mandates disclosure of nonpharmacologic alternatives, FDA boxed warnings, off-label use status, drug interactions, and adverse effect monitoring procedures as part of informed consent.

Requires facilities to provide written notice every 6 months of recommended dosage adjustments and residents' right to revoke consent and receive gradual dose reductions.

Prohibits use of psychotherapeutic drugs for resident discipline, convenience, or chemical restraint except in emergencies, with violations classified as misdemeanors.

Requires State Department of Public Health to develop a standardized informed consent form available by December 31, 2025, with facilities exempt from including written consent forms until the template is available.